ADMA Biologics Target of Unusually High Options Trading (NASDAQ:ADMA)

ADMA Biologics, Inc. (NASDAQ:ADMA) saw some unusual options trading on Tuesday. Stock traders acquired 7,765 call options on the stock. This represents an increase of 178% compared to the average volume of 2,789 call options.

ADMA Biologics Stock Up 5.9 %

Shares of ADMA stock opened at $22.15 on Wednesday. The company has a market capitalization of $5.24 billion, a price-to-earnings ratio of 79.11 and a beta of 0.53. The company has a debt-to-equity ratio of 0.48, a current ratio of 7.09 and a quick ratio of 3.26. The company’s fifty day moving average price is $17.96 and its 200-day moving average price is $18.19. ADMA Biologics has a one year low of $5.91 and a one year high of $23.64.

Wall Street Analyst Weigh In

Separately, Cantor Fitzgerald restated an “overweight” rating and issued a $25.00 price target on shares of ADMA Biologics in a research report on Tuesday, March 4th.

Institutional Investors Weigh In On ADMA Biologics

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Lord Abbett & CO. LLC purchased a new stake in shares of ADMA Biologics during the third quarter worth about $61,858,000. Raymond James Financial Inc. bought a new position in ADMA Biologics in the 4th quarter worth approximately $19,076,000. EWG Elevate Inc. purchased a new stake in ADMA Biologics during the 4th quarter valued at approximately $480,000. Allspring Global Investments Holdings LLC raised its position in shares of ADMA Biologics by 1,144.4% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 2,841,849 shares of the biotechnology company’s stock valued at $51,016,000 after buying an additional 2,613,482 shares during the last quarter. Finally, Veracity Capital LLC lifted its holdings in shares of ADMA Biologics by 117.0% in the fourth quarter. Veracity Capital LLC now owns 46,415 shares of the biotechnology company’s stock worth $796,000 after buying an additional 25,030 shares in the last quarter. 75.68% of the stock is owned by institutional investors.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.